Table 2.
Association between Syk expression and clinicopathological criteria
| Variable | Syk-c expression | Syk-n expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Low | High | P value | Low | High | P value | ||||
| Age | |||||||||
| ≤ 62 | 30 (6.8%) | 184 (41.8%) | 0.492 | 51 (11.6%) | 163 (37.0%) | 0.447 | |||
| > 62 | 37 (8.4%) | 189 (43.0%) | 61 (13.9%) | 65 (37.5%) | |||||
| Histological subtypes | |||||||||
| HGSC | 25 (5.7%) | 247 (56.0%) | 2.115E−11* | 57 (12.9%) | 215 (48.8%) | 1.6E−5* | |||
| Mucinous | 9 (2.0%) | 34 (7.7%) | 10 (2.3%) | 33 (7.5%) | |||||
| Endometrioid | 9 (2.0%) | 45 (10.2%) | 16 (3.6%) | 38 (8.6%) | |||||
| CCC | 23 (5.2%) | 21 (4.8%) | 25 (5.7%) | 19 (4.3%) | |||||
| LGSC | 1 (0.2%) | 17 (3.9%) | 4 (0.9%) | 14 (3.2%) | |||||
| SBOT | 0 (0.0%) | 10 (2.3%) | 0 (0.0%) | 10(2.3%) | |||||
| Grade | |||||||||
| 1 | 4 (0.9%) | 29 (6.6%) | 0.813 | 7 (1.6%) | 26 (5.9%) | 0.174 | |||
| 2 | 9 (2.0%) | 56 (12.7%) | 11 (2.5%) | 54 (12.2%) | |||||
| 3 | 54 (12.2%) | 289 (65.5%) | 94 (21.3%) | 249 (56.5%) | |||||
| Stage | |||||||||
| I | 36 (8.3%) | 123 (28.3%) | 0.013* | 50 (11.5%) | 109 (25.1%) | 0.209 | |||
| II | 6 (1.4%) | 43 (9.9%) | 12 (2.8%) | 37 (8.5%) | |||||
| III | 20 (4.6%) | 175 (40.3%) | 42 (9.7%) | 153 (35.3%) | |||||
| IV | 5 (1.2%) | 26 (6.0%) | 8 (1.8%) | 23 (5.3%) | |||||
| Residual disease | |||||||||
| No residual tumour | 44 (11.3%) | 195 (50.0%) | 0.227 | 72 (18.5%) | 167 (42.8%) | 0.076 | |||
| Residual tumour (< 2 cm) | 5 (1.3%) | 41 (10.5%) | 10 (2.6%) | 36 (9.2%) | |||||
| Residual tumour (> 2 cm) | 13 (3.3%) | 92 (23.6%) | 20 (5.1%) | 85 (21.8%) | |||||
| Response to platinum-based chemotherapy | |||||||||
| Chemo-refractory | 6 (2.1%) | 24 (8.5%) | 0.589* | 13 (4.6%) | 17 (6.0%) | 0.154 | |||
| Chemo-resistance | 2 (0.7%) | 19 (6.7%) | 6 (2.1%) | 15 (5.3%) | |||||
| Chemo-sensitivity | 35 (12.4%) | 196 (69.5%) | 61 (21.6%) | 170 (60.3%) | |||||
| Response to taxane-containing (i.e., paclitaxel, docetaxel) chemotherapy regimens | |||||||||
| Chemo-resistance | 3 (2.5%) | 18 (14.8%) | 0.774* | 11 (9.0%) | 10 (8.2%) | 0.006 | |||
| Chemo-sensitivity | 17 (13.9%) | 84 (68.9%) | 23 (18.9%) | 78 (63.9%) | |||||
HGSC high-grade serous carcinoma, LGSC low-grade serous carcinoma, CCC clear-cell carcinoma, SBOT serous borderline ovarian tumour
*Expected count less than 5. Significant P values are indicated by bold font